Dynavax Technologies Corp DVAX shares are trading higher on Tuesday, after the company said it intends to provide an update on early-stage coronavirus vaccine candidate collaborations. The company expects at least one of its collaborators to commence a Phase 1 clinical trial of a potential vaccine as early as July.
Dynavax Technologies is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Dynavax shares were trading up 22.74% at $5.96 on Tuesday. The stock has a 52-week range between $7.20 and $1.80.
Related Links:
Moderna To Raise $1.3B In A Public Offering As Coronavirus Vaccine Trials See Progress
Gilead Reports Q1 Earnings Beat, Anticipates Short-Term Impact From Coronavirus
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.